Abstract
An article recently published in the World Journal of Diabetes, provides valuable insights into using immune biomarkers to identify renal damage in pediatric patients with newly diagnosed type 1 diabetes (T1D). Although these findings are promising, clinical translation of these immune markers into routine diagnostics and preventive care remains challenging. In this letter, we propose building on the authors' work by exploring the integration of immune biomarkers into a more comprehensive dynamic risk stratification model for early renal injury. Combining immune system indicators with metabolic and genetic factors could enhance the predictive accuracy and support more personalized interventions. Longitudinal studies are needed to evaluate temporal changes in immune biomarkers and their association with long-term renal outcomes in children with T1Ds. Immunomodulatory therapies targeting early immune dysfunction can prevent or slow the progression of diabetic nephropathy. By incorporating these aspects, we hope to translate immune biomarkers from research into practical clinical tools, ultimately improving patient outcomes and reducing the burden of kidney-related complications in pediatric diabetes.